Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Expanded Prospective Payment System and Use of and Outcomes with Home Dialysis by Race and Ethnicity in the United States.

Shen JI, Erickson KF, Chen L, Vangala S, Leng L, Shah A, Saxena AB, Perl J, Norris KC.

Clin J Am Soc Nephrol. 2019 Jul 18. pii: CJN.00290119. doi: 10.2215/CJN.00290119. [Epub ahead of print]

PMID:
31320318
2.

Nephrology Advanced Practitioners in the United States, 2010-2018.

Zuber K, Davis J, Erickson KF.

Clin J Am Soc Nephrol. 2019 Jul 11. pii: CJN.01600219. doi: 10.2215/CJN.01600219. [Epub ahead of print] No abstract available.

PMID:
31296504
3.

The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins.

Walther CP, Erickson KF.

Kidney Int. 2019 Jul;96(1):22-25. doi: 10.1016/j.kint.2019.02.029.

PMID:
31229030
4.

Association of Hospitalization and Mortality Among Patients Initiating Dialysis With Hemodialysis Facility Ownership and Acquisitions.

Erickson KF, Zhao B, Niu J, Winkelmayer WC, Bhattacharya J, Chertow GM, Ho V.

JAMA Netw Open. 2019 May 3;2(5):e193987. doi: 10.1001/jamanetworkopen.2019.3987.

5.

Predialysis Nephrology Care and Incident Atrial Fibrillation in Older Patients With ESKD Initiating Dialysis.

Anumudu S, Airy M, Erickson KF, Navaneethan SD, Chang TI, Winkelmayer WC, Niu J.

Kidney Int Rep. 2019 Feb 13;4(5):679-687. doi: 10.1016/j.ekir.2019.02.007. eCollection 2019 May.

6.

Integrated Care in ESKD: A Perspective of Nephrologists.

Brady BM, Erickson KF.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):451-453. doi: 10.2215/CJN.13081118. Epub 2019 Jan 29. No abstract available.

PMID:
30696662
7.

Market Consolidation and Mortality in Patients Initiating Hemodialysis.

Erickson KF, Winkelmayer WC, Ho V, Bhattacharya J, Chertow GM.

Value Health. 2019 Jan;22(1):69-76. doi: 10.1016/j.jval.2018.06.008. Epub 2018 Jul 27.

PMID:
30661636
8.

Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014).

Awan AA, Niu J, Pan JS, Erickson KF, Mandayam S, Winkelmayer WC, Navaneethan SD, Ramanathan V.

Am J Nephrol. 2018;48(6):472-481. doi: 10.1159/000495081. Epub 2018 Nov 23.

PMID:
30472701
9.

Did Medicaid Expansion Reduce Mortality Among Patients Initiating Dialysis for Irreversible Kidney Failure?

Erickson KF, Ho V, Winkelmayer WC.

JAMA. 2018 Dec 4;320(21):2206-2208. doi: 10.1001/jama.2018.14291. No abstract available.

PMID:
30422240
10.

Evaluating the Evidence behind Policy Mandates in US Dialysis Care.

Erickson KF, Winkelmayer WC.

J Am Soc Nephrol. 2018 Dec;29(12):2777-2779. doi: 10.1681/ASN.2018090905. Epub 2018 Nov 2. No abstract available.

PMID:
30389727
11.

Health Insurance in the First 3 Months of Hemodialysis and Early Vascular Access.

Lin E, Mell MW, Winkelmayer WC, Erickson KF.

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1866-1875. doi: 10.2215/CJN.06660518. Epub 2018 Nov 1.

PMID:
30385594
12.

Patient-Reported Experiences of Dialysis Care Within a National Pay-for-Performance System.

Brady BM, Zhao B, Niu J, Winkelmayer WC, Milstein A, Chertow GM, Erickson KF.

JAMA Intern Med. 2018 Oct 1;178(10):1358-1367. doi: 10.1001/jamainternmed.2018.3756.

PMID:
30208398
13.

Making Policy in the Dark: The Use of Activated Vitamin D Under Bundled Payments for Dialysis Care.

Awan AA, Thomas SS, Erickson KF.

Am J Kidney Dis. 2018 Aug;72(2):161-163. doi: 10.1053/j.ajkd.2018.04.011. No abstract available.

PMID:
30037474
14.

The Role of Big Data in the Development and Evaluation of US Dialysis Care.

Erickson KF, Qureshi S, Winkelmayer WC.

Am J Kidney Dis. 2018 Oct;72(4):560-568. doi: 10.1053/j.ajkd.2018.04.007. Epub 2018 Jun 18.

PMID:
29921451
15.

Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.

Kramer JR, Puenpatom A, Erickson KF, Cao Y, Smith D, El-Serag HB, Kanwal F.

J Viral Hepat. 2018 Nov;25(11):1270-1279. doi: 10.1111/jvh.12937. Epub 2018 Jul 3.

PMID:
29851265
16.

Market Competition and Health Outcomes in Hemodialysis.

Erickson KF, Zheng Y, Ho V, Winkelmayer WC, Bhattacharya J, Chertow GM.

Health Serv Res. 2018 Oct;53(5):3680-3703. doi: 10.1111/1475-6773.12835. Epub 2018 Feb 22.

PMID:
29468675
17.

Employment among Patients Starting Dialysis in the United States.

Erickson KF, Zhao B, Ho V, Winkelmayer WC.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):265-273. doi: 10.2215/CJN.06470617. Epub 2018 Jan 18.

18.

Health Insurance and the Use of Peritoneal Dialysis in the United States.

Perez JJ, Zhao B, Qureshi S, Winkelmayer WC, Erickson KF.

Am J Kidney Dis. 2018 Apr;71(4):479-487. doi: 10.1053/j.ajkd.2017.09.024. Epub 2017 Dec 23.

19.

A Case for More Frequent, Not Just Earlier, Nephrology Care of Patients Approaching ESRD?

Qureshi S, Erickson KF, Winkelmayer WC.

Am J Kidney Dis. 2017 Aug;70(2):155-157. doi: 10.1053/j.ajkd.2017.04.016. No abstract available.

PMID:
28739124
20.

Home Alone: Does Modality Matter? Revisiting Hospital Readmissions in Dialysis.

Shen JI, Dave NN, Erickson KF.

Am J Kidney Dis. 2017 Jul;70(1):1-3. doi: 10.1053/j.ajkd.2017.04.006. No abstract available.

PMID:
28646981
21.

Hemodialysis Hospitalizations and Readmissions: The Effects of Payment Reform.

Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J.

Am J Kidney Dis. 2017 Feb;69(2):237-246. doi: 10.1053/j.ajkd.2016.08.033. Epub 2016 Nov 14.

22.

Consolidation in the Dialysis Industry, Patient Choice, and Local Market Competition.

Erickson KF, Zheng Y, Winkelmayer WC, Ho V, Bhattacharya J, Chertow GM.

Clin J Am Soc Nephrol. 2017 Mar 7;12(3):536-545. doi: 10.2215/CJN.06340616. Epub 2016 Nov 9.

23.

Effects of physician payment reform on provision of home dialysis.

Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J.

Am J Manag Care. 2016 Jun 1;22(6):e215-23.

24.

Federal Funding for Kidney Disease Research: A Missed Opportunity.

Mendu ML, Erickson KF, Hostetter TH, Winkelmayer WC, Olan G, Meyer RN, Hakim R, Sedor JR.

Am J Public Health. 2016 Mar;106(3):406-7. doi: 10.2105/AJPH.2015.303009. No abstract available.

25.

A Cost Analysis of Tolerance Induction for Two-Haplotype Match Kidney Transplant Recipients.

Erickson KF, Winkelmayer WC, Busque S, Lowsky R, Scandling JD, Strober S.

Am J Transplant. 2016 Jan;16(1):371-3. doi: 10.1111/ajt.13530. Epub 2015 Nov 9. No abstract available.

26.

Measuring comorbidity in patients receiving dialysis: can we do better?

O'Shaughnessy MM, Erickson KF.

Am J Kidney Dis. 2015 Nov;66(5):731-4. doi: 10.1053/j.ajkd.2015.07.001. Epub 2015 Jul 23. No abstract available.

PMID:
26210068
27.

Overlooked care transitions: an opportunity to reduce acute care use in ESRD.

Erickson KF, Kurella Tamura M.

Clin J Am Soc Nephrol. 2015 Mar 6;10(3):347-9. doi: 10.2215/CJN.00220115. Epub 2015 Feb 3. No abstract available.

28.

Provider visit frequency and vascular access interventions in hemodialysis.

Erickson KF, Mell MW, Winkelmayer WC, Chertow GM, Bhattacharya J.

Clin J Am Soc Nephrol. 2015 Feb 6;10(2):269-77. doi: 10.2215/CJN.05540614. Epub 2015 Jan 13.

29.

Provider Visits and Early Vascular Access Placement in Maintenance Hemodialysis.

Erickson KF, Mell M, Winkelmayer WC, Chertow GM, Bhattacharya J.

J Am Soc Nephrol. 2015 Aug;26(8):1990-7. doi: 10.1681/ASN.2014050464. Epub 2014 Dec 1.

30.

Physician visits and 30-day hospital readmissions in patients receiving hemodialysis.

Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J.

J Am Soc Nephrol. 2014 Sep;25(9):2079-87. doi: 10.1681/ASN.2013080879. Epub 2014 May 8.

31.

Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older US patients.

Shen JI, Montez-Rath ME, Mitani AA, Erickson KF, Winkelmayer WC.

Pharmacoepidemiol Drug Saf. 2014 May;23(5):515-25. doi: 10.1002/pds.3595. Epub 2014 Feb 18.

32.

Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Erickson KF, Chertow GM, Goldhaber-Fiebert JD.

Ann Intern Med. 2014 Jan 21;160(2):143. doi: 10.7326/L14-5001-7. No abstract available.

33.

Medicare Reimbursement Reform for Provider Visits and Health Outcomes in Patients on Hemodialysis.

Erickson KF, Winkelmayer WC, Chertow GM, Bhattacharya J.

Forum Health Econ Policy. 2014 Jan 1;17(1):53-77.

34.

Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Erickson KF, Chertow GM, Goldhaber-Fiebert JD.

Ann Intern Med. 2013 Sep 17;159(6):382-9. doi: 10.7326/0003-4819-159-6-201309170-00004.

35.

Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.

Erickson KF, Japa S, Owens DK, Chertow GM, Garber AM, Goldhaber-Fiebert JD.

J Am Coll Cardiol. 2013 Mar 26;61(12):1250-8.

36.

Variation in nephrologist visits to patients on hemodialysis across dialysis facilities and geographic locations.

Erickson KF, Tan KB, Winkelmayer WC, Chertow GM, Bhattacharya J.

Clin J Am Soc Nephrol. 2013 Jun;8(6):987-94. doi: 10.2215/CJN.10171012. Epub 2013 Feb 21.

37.

Interaction between GFR and risk factors for morbidity and mortality in African Americans with CKD.

Erickson KF, Lea J, McClellan WM.

Clin J Am Soc Nephrol. 2013 Jan;8(1):75-81. doi: 10.2215/CJN.03340412. Epub 2012 Oct 18.

38.

The challenges of cost-effectiveness analyses for the clinician.

Erickson KF, Winkelmayer WC.

Am J Kidney Dis. 2010 Dec;56(6):1023-5. doi: 10.1053/j.ajkd.2010.10.001. No abstract available.

Supplemental Content

Loading ...
Support Center